Natco Pharma has reported a stark profit decline in the first quarter, largely driven by reduced sales of its leading cancer drug, lenalidomide. This led to a pronounced drop in consolidated.
Syndicated via official news feed
Syndicated feed content with full publisher credit.
Continue reading verified coverage and related developments on this desk.
Latest developments and reports from the desk
Latest fundraising values the six-year-old company at about $650mn as it aims to be ‘daily luxury brand’
Stéphane Boujnah has obsessively chased acquisitions to compete with larger rivals
As governments borrow more, the buyers of their debt are changing